Fierce Biotech Summit
Boston, MA 02210
Event summary
Cooley is proud to sponsor the Fierce Biotech Summit, which brings together leaders and experienced executives to discuss exciting advancements and the potential of new innovations. This annual two-day gathering focuses on the future of biotechnology by covering topics such as the biotech initial public offering (IPO) outlook, developments in cell therapy, and the transition from corporate communications to corporate affairs. Industry leaders also will dive deep into how the industry has navigated regulatory challenges and market changes through strategic deals and innovative approaches.
Featured agenda item
Monday, September 30, 2024 | 4:00 – 4:45 pm EDT
Charting the Biotech IPO Frontier: Market Trends, Financial Outlook, and Future Projections
After a two-year dry spell, biotech IPOs saw a resurgence in the first quarter of 2024, reaching prepandemic levels and collectively raising more than $1.3 billion, signaling signs of recovery in the market. Cooley partner Div Gupta will be among the panelists for a discussion on the revival of biotech IPOs in 2024 – and their impact on innovation and funding. The panelists will:
- Review the current landscape of recent biotech IPOs.
- Compare the explosive growth of biotech IPOs and SPACs (special purpose acquisition companies) in 2020 and its aftermath to this year’s conditions.
- Discuss the emerging trends and patterns observed in biotech IPOs, such as investor sentiment, market dynamics, and regulatory influences.
- Interpret the implications of these trends on funding for biotech innovation and research, including the effects on startups and venture capital investments.
- Predict and discuss projections for biotech IPOs in 2025 and beyond.
Panelists
- Jordan Saxe (moderator) – Head of healthcare, listings and capital markets at Nasdaq
- Alethia Young – Chief financial officer of Bicycle Therapeutics
- Div Gupta – Partner at Cooley
- Troy Ignelzi – Chief financial officer of Rapport Therapeutics
- Andrew Lam – Managing director and head of biotech private equity at Ally Bridge Group
For more information, please email Erica Koljonen.
This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered Attorney Advertising and is subject to our legal notices.